Results 11 to 20 of about 5,542 (243)
Expected Impact of Biosimilars on the Pharmaceutical Companies.
Iranian journal of medical sciences, 2021 In the last three decades, biological products have gradually developed to be an essential basis in the pharmaceutical industry. Advancements in this field have encouraged the frontiers of science to bring life-saving treatments to patients suffering from incurable diseases, such as cancers and has also assisted clinicians in managing chronic diseases ...
Golshani, Shiva, Faramarzi, Mohammad Ali
openaire +3 more sources
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure [PDF]
Frontiers in Pharmacology, 2021 Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies.
Vogler, Sabine +4 more
openaire +4 more sources
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS [PDF]
Current Pharmaceutical Biotechnology, 2016 Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-
Kerry M, Wooding +2 more
openaire +2 more sources
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? [PDF]
The European Journal of Health Economics, 2013 Biological medicines contain a biological substance that is produced by or derived from a living organism. The active substances of biologicals are usually larger and more complex than those of chemically derived medicines (non-biological medicine). Biologicals are used for the treatment of chronic and life-threatening diseases such as cancer, multiple
Farfan-Portet, María-Isabel +4 more
openaire +2 more sources
Generic Medicines and Biosimilars: Impact on Global Pharmaceutical Policy
, 2020 Patient access to safe and cost-effective treatment is an important goal for the healthcare system. The development of biosimilar compounds and generic medicines is interesting to the industry and society to reduce healthcare costs, fulfill the needs of healthcare stakeholders and potentially increase accessibility to patients.
Ibrahim, Mohamed Izham Mohamed +1 more
openaire +3 more sources
BMC Health Services Research, 2022 Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in
Alen Brkic +10 more
doaj +1 more source
Pharmaceuticals, 2021 Slow uptake of biosimilars in some regions is often attributed to a lack of knowledge combined with concerns about safety and efficacy. To alleviate physician and patient apprehensions, regulatory reviews from four major regulatory authorities (RAs ...
Beverly Ingram +3 more
doaj +1 more source
Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals [PDF]
Journal of Veterinary Science & Medicine, 2016 Recent price hikes by pharmaceutical companies underscore the importance of competition in an industry that often sets prices according to what the market will bear. A steady pipeline of generics and biosimilars is the surest check to the rising prices of drugs and biologics.
openaire +1 more source
Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]
, 2017 Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core +1 more source
The impact of the Medicines Control Council backlog and fast-track review system on access to innovative and new generic and biosimilar medicines of public health importance in South Africa [PDF]
, 2016 The fast-track registration policy of the South African National Department of Health allows for rapid registration of new medicines of public health importance and of all medicines on the Essential Medicines List, most of which are generics. No limit is
Leng, HMJ, Pollock, AM, Sanders, D
core +3 more sources